Friday, February 27, 2015 Last update: 7:03 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

GeoVax Labs, Inc.

News articles for GeoVax Labs, Inc.:

Wednesday, December 10, 2014

Thursday, September 4, 2014

Thursday, May 1, 2014

Wednesday, March 19, 2014

Wednesday, March 5, 2014

  • GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update
    ATLANTA, GA -- (Marketwired) -- 03/05/14 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2013 and provided the following corporate update. Corporate Update Therapeutic HIV Vaccine In January of this year, GeoVax announced ... read more

Tuesday, January 28, 2014

  • GeoVax Presents at the Phacilitate Vaccine Forum 2014
    ATLANTA, GA -- (Marketwired) -- 01/28/14 -- GeoVax Labs, Inc. (OTCQB: GOVX) announced today that its Chief Scientific Officer, Dr. Harriet Robinson, presented information on the selection of antigens and antigen combinations for the elicitation of protective antibody responses for HIV at the Phacilitate Vaccine Forum 2014 on ... read more

Thursday, January 23, 2014

Monday, January 13, 2014

Thursday, December 12, 2013

  • GeoVax Announces $1.65M Private Placement
    ATLANTA, GA -- (Marketwired) -- 12/12/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series B ... read more

Friday, November 22, 2013

  • GeoVax Appoints Dr. Arban Domi as Director, Vector Development
    ATLANTA, GA -- (Marketwired) -- 11/22/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today announced the appointment of Arban Domi, Ph.D., as its Director, Vector Development. Dr. Domi will not only be a key player in the continued development of GeoVax's ... read more

Monday, November 18, 2013

Tuesday, November 12, 2013

  • GeoVax Reports 2013 Third Quarter Financial Results
    ATLANTA, GA -- (Marketwired) -- 11/12/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today reported financial results and recent developments for the three and nine months ended September 30, 2013. GeoVax reported a net loss of $190,148 ($0.01 per share) for ... read more

Wednesday, October 9, 2013

  • GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV
    ATLANTA, GA -- (Marketwired) -- 10/09/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, today presented additional results from HVTN 205, a multicenter, randomized Phase 2a trial evaluating the safety and immunogenicity of the Company's first generation preventive HIV vaccine, at ... read more

Monday, October 7, 2013

  • GeoVax Receives Notice of Patent Allowance for DNA/MVA Vaccine for HIV/AIDS
    ATLANTA, GA -- (Marketwired) -- 10/07/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing preventive and therapeutic HIV vaccines, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 10/336,566 entitled, "Compositions and Methods for ... read more

Monday, August 12, 2013

Thursday, August 1, 2013

Thursday, May 2, 2013

Monday, March 11, 2013

  • GeoVax Labs Reports 2012 Financial Results and Progress
    ATLANTA, GA -- (Marketwire) -- 03/11/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year ended December 31, 2012 and provided a business update. "GeoVax continues its successful, steady progress with the clinical development of HIV/AIDS ... read more

Wednesday, January 23, 2013

  • GeoVax Labs Launches New Corporate Website
    ATLANTA, GA -- (Marketwire) -- 01/23/13 -- GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, unveiled its new website January 23rd. The site, www.geovax.com, incorporates numerous features to make browsing a more fruitful experience for the Company's current and potential investors. The ... read more

Tuesday, January 15, 2013

  • GeoVax Labs Releases Update Letter to Shareholders
    ATLANTA, GA -- (Marketwire) -- 01/15/13 -- Robert T. McNally, Ph.D., President & CEO of GeoVax Labs (OTCQB: GOVX), along with David A. Dodd, Chairman of the Board, today issued the following update letter to shareholders: Dear Fellow Shareholders, Since our last shareholder update letter in May 2012, we have continued ... read more